

Published Data in metastatic Pancreatic Cancer

The following tables summarize the prospective and retrospective studies on the use of SIR-Spheres Y-90 resin microspheres in the treatment of pancreatic cancer liver metastases (LM). Tumor response and/or survival results are listed accordingly.

For studies in which multiple tumor types were investigated, outcomes include all tumor types, unless otherwise noted.

Prospective studies

Treatment/Line of Therapy (n)	N (n)	ORR ^a	SD	PFS	Median survival	Reference
SIR-Spheres ^b 1st line (13); 2nd line (1)	14	93%	71%	5.2 mo (liver), 4.4 mo (any site)	5.5 mo	Gibbs, 2015
SIR-Spheres 2nd line (7)	7	29%	14%	nr	nr	Cao, 2010

Retrospective studies

Treatment/Line of Therapy (n)	N (n)	ORR ^a	SD	PFS	Median survival	Reference
LRT, including microwave ablation (nr); radiofrequency ablation (nr); cryoablation (nr); TACE (nr); SIRT (nr), either SIR-Spheres or TheraSphere ^c ≥1st-line	20	mRECIST: In-field: 77.7% Out-of-field: 11.1%	mRECIST: In-field 22.2% Out-of-field 11.1%	nr	LRT: 9.7 mo From diagnosis of LM: 16.25 mo From diagnosis of pancreatic cancer: 25 mo	Bailey, 2019
SIR-Spheres ≥2nd line (32) ^d	33	42%, 8/19 pts	37%, 7/19 pts	nr	8.1 mo ^e 20.8 mo ^f	Kim, 2019
SIR-Spheres ≥1st line (16)	16	31%	38%	4.9 mo (local), 3.4 mo (systemic)	12.5 mo	Kim, 2016
SIR-Spheres ≥2nd line (17)	17	41%	nr	2.9 mo	8.8 mo	Michl, 2016
SIR-Spheres ≥1st line (19)	19	47% ^g	nr	3.4 mo	9.0 mo	Michl, 2014
SIR-Spheres + TomoTherapy + 5-FU ≥1st line (7); SIR-Spheres + 5-FU ≥1st line (4)	11	0% (CT) 66% (PET) ^h	100%	nr	5.4 mo ⁱ	Gulec, 2009

In an effort to facilitate the review of data in this table, data originally reported as days/weeks were converted to months.

5-FU: 5-fluorouracil; CT: computed tomography; LRT: locoregional therapy; mo: months; mRECIST: modified RECIST; nr: not reported; ORR: objective response rate (complete response [CR] + partial response [PR]); PET: positron emission tomography; PFS: progression-free survival; pts: patients; SD: stable disease; SIRT: selective internal radiation therapy; TACE: transarterial chemoembolization.

- a. By RECIST (Response Evaluation Criteria In Solid Tumors) unless otherwise indicated.
- b. SIR-Spheres Y-90 resin microspheres.
- c. Therasphere Yttrium-90 Glass Microspheres.
- d. Record of line of therapy was not available for 1 patient.
- e. Median survival from SIRT.
- f. Median survival from diagnosis.
- g. The authors of this article have not provided a definition for this variable.
- h. By positron emission tomography using total lesion glycolysis.
- i. Months calculated from weeks using Google calculator: 1 week = 0.230137 months.

References:

1. Gibbs P *et al.* *BMC Cancer* 2015; **15**: 802.
2. Cao C *et al.* *Tumori* 2010; **96**: 955–958.
3. Bailey RE *et al.* *J Gastrointest Oncol* 2019; **10**: 688–694.
4. Kim AY *et al.* *J Vasc Interv Radiol* 2019; **30**: 298–304.
5. Kim AY *et al.* *BMC Cancer* 2016; **16**: 492.
6. Michl M *et al.* *J Nucl Med* 2016; **57**: 355–360.
7. Michl M *et al.* *Oncology* 2014; **86**: 24–32.
8. Gulec SA *et al.* *J Interv Oncol* 2009; **2**: 84–92.

SIR-Spheres® is a registered trademark of Sirtex SIR-Spheres Pty Ltd

Last update with data identified through September 30, 2019

219-EUA-0919

Advancing to the next level.



Sirtex Medical Europe GmbH
Joseph-Schumpeter-Allee 33, 53227 Bonn, Germany

www.sirtex.com